Screener
Wave Life Sciences WVE Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities, Series A preferred shares, and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $20,362 | $15,700 |
| Accrued expenses and other current liabilities | 18,242 | 26,564 |
| Current portion of deferred revenue | 8,703 | 44,440 |
| Current portion of operating lease liability | 3,508 | 8,361 |
| Total current liabilities | 50,815 | 95,065 |
| Long-term liabilities: |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's accrued expenses?
- Wave Life Sciences (WVE) reported accrued expenses of $18.24M in Q2 2026.
- How has Wave Life Sciences's accrued expenses changed year-over-year?
- Wave Life Sciences's accrued expenses increased by 40.0% year-over-year, from $13.03M to $18.24M.
- What is the long-term trend for Wave Life Sciences's accrued expenses?
- Over 5 years (2020 to 2025), Wave Life Sciences's accrued expenses has grown at a 17.3% compound annual growth rate (CAGR), from $11.97M to $26.56M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Wave Life Sciences's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude